The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants

BACKGROUND: In vitro studies suggesting that REGEN-COV (casirivimab plus imdevimab monoclonal antibodies) had poor efficacy against Omicron-variant SARS-CoV-2 infection led to amendment of REGEN-COV’s Emergency Use Authorization to recommend use only in regions without high Omicron prevalence. REGEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Gershengorn, Hayley B., Patel, Samira, Ferreira, Tanira, Das, Sankalp, Parekh, Dipen J., Shukla, Bhavarth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718412/
https://www.ncbi.nlm.nih.gov/pubmed/36459537
http://dx.doi.org/10.1371/journal.pone.0278770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718412/
https://www.ncbi.nlm.nih.gov/pubmed/36459537
http://dx.doi.org/10.1371/journal.pone.0278770

Ejemplares similares